on MAAT PHARMA (isin : FR0012634822)
MaaT Pharma launches a capital increase
MaaT Pharma, a biotechnology company, announces the launch of a capital increase of approximately €9 million. This initiative includes a Global Offering consisting of a Private Placement for qualified investors and a public offering via PrimaryBid for retail investors. The price is set at €3.48 per share.
The fundraising will support the commercialization of Xervyteg® in Europe, pending approval by the EMA, and will extend financial visibility until summer 2026. Subscription commitments by current shareholders and directors total 3 million euros, with an intention of an additional 1.5 million euros.
The results of the Global Offering will be announced on November 14, 2025. This financing strategy will allow MaaT Pharma to continue its clinical developments and ensure its operation beyond 2026.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MAAT PHARMA news